Form 4: Artiva Biotherapeutics CEO Sells Shares
Insider Transaction (Form 4)
Fred Aslan, Chief Executive Officer and a Director of Artiva Biotherapeutics, Inc., sold 23,463 shares of common stock on October 6, 2026 for $7.20 per share.
Summary
- Open-market sale: disposed of 23,463 Common Stock at $7.20 ($168,880) on October 6, 2026; holds 1,519,606 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $168,880 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Fred Aslan — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-06 | Open-market sale | Common Stock | 23,463 | $7 | $168.9K | 1,519,606 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-06 | Open-market sale (23,463 shares) |
Keywords
insider transaction, Form 4, ARTV, Artiva Biotherapeutics, Inc., bearish, Fred Aslan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.